FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Laurus Labs's Free Cash Flow for the
three
months ended in Mar. 2026 was ₹0 Mil. Laurus Labs's Revenue for the
three
months ended in Mar. 2026 was ₹17,199 Mil. Therefore, Laurus Labs's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Laurus Labs's FCF Margin % or its related term are showing as below:
BOM:540222'
s FCF Margin % Range Over the Past 10 Years
Min: -2.43 Med: 0.82 Max: 8.24
Current: 8.24
During the past 13 years, the highest FCF Margin % of Laurus Labs was 8.24%. The lowest was -2.43%. And the median was 0.82%.
BOM:540222's FCF Margin % is ranked better than 65.69% of 956
companies
in the Drug Manufacturers industry
Industry Median: 2.48
vs BOM:540222: 8.24
Laurus Labs FCF Margin % Related Terms
Laurus Labs FCF Margin % Historical Data
* Premium members only.
The historical data trend for Laurus Labs's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laurus Labs FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Laurus Labs's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laurus Labs (BOM:540222) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Laurus Labs and its competitors. According to the industry distribution chart, Laurus Labs ranks #328 out of 956 companies in the Drug Manufacturers industry, placing it in the top 34.3%.
Is Laurus Labs' FCF Margin % too high?
Laurus Labs' current FCF Margin % is 0.00%. Based on the distribution chart, Laurus Labs ranks #328 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laurus Labs ranks #328 out of 956 companies for FCF Margin %. This puts Laurus Labs in the upper half of its industry. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Laurus Labs and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laurus Labs's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹697.80, compared to a current price of ₹1,502.90 — trading 115.4% above its estimated fair value. The current FCF Margin % is 0.00%. Laurus Labs' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laurus Labs (BOM:540222) Overvalued in 2026?
Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued.
The current stock price of ₹1,502.90 is trading 115.4% above its estimated GF Value™ of ₹697.80.
GuruFocus considers Laurus Labs to be Significantly Overvalued.
Key valuation signals for BOM:540222:
FCF Margin %: 0.00%
GF Value™: ₹697.80 vs. price of ₹1,502.90 (115.4% above fair value)
No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score
Get the complete analysis for BOM:540222
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540222 has been successfully added to your 
